The May update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs:

Amphotericin B Liposomal Injection (AmBisome^®)
- Amphotericin B liposomal injection is used to treat fungal infections such as cryptococcal meningitis and visceral leishmaniasis
Dexamethasone Injection (Decadron^®& Available generically)
- Dexamethasone injection is used to treat severe allergic reactions, certain types of edema, gastrointestinal disease, and certain types of arthritis, and other diseases treated by corticosteroids
Reslizumab Injection (Cinqair^®)
- Reslizumab injection is used along with other medications to treat asthma

FDA MedWatch Alerts – Monograph Revisions

Aripiprazole
- Warning regarding compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported
Ticagrelor and Vortioxetine
- Brand name change for vortioxetine (Brintellix) due to name confusion with ticagrelor (Brilinta)
Olanzapine and Olanzapine injection
- Rare, but serious skin reactions
Fluoroquinolones
- Serious adverse effects generally outweigh benefits for patients with sinusitis, bronchitis, and uncomplicated UTIs
- Affected monographs:
  - Ciprofloxacin, ciprofloxacin injection, gemifloxacin, levofloxacin, levofloxacin injection, moxifloxacin, moxifloxacin injection, ofloxacin